-
Outcome of the PRAC review of COVID-19 Vaccine Janssen
Outcome of the PRAC review of COVID-19 Vaccine Janssen
-
Outcome of the PRAC review of COVID-19 Vaccine Janssen
Outcome of the PRAC review of COVID-19 Vaccine Janssen
EMA’s safety committee (PRAC) finds possible link to very rare cases of unusual blood clots with low blood platelets but overall benefit-risk remains positive
-
EMA continues to monitor COVID-19 vaccine AstraZeneca
EMA continues to monitor COVID-19 vaccine AstraZeneca
-
EMA continues to monitor COVID-19 vaccine AstraZeneca
EMA continues to monitor COVID-19 vaccine AstraZeneca
EMA to provide further context on risk of very rare blood clots with low blood platelets that occurred after vaccination with Vaxzevria
-
PRAC highlights April 2021
PRAC highlights April 2021
-
PRAC highlights April 2021
PRAC highlights April 2021
Outcomes from the April meeting cover all aspects of the risk management of the use of medicines, including COVID-19 vaccines
-
Development, evaluation and monitoring of COVID-19 vaccines
Development, evaluation and monitoring of COVID-19 vaccines
-
Development, evaluation and monitoring of COVID-19 vaccines
Development, evaluation and monitoring of COVID-19 vaccines
Read about how EMA is ensuring vaccines for COVID-19 meet the highest standards of quality, safety & efficacy while their development and approval is sped up due to the public health emergency.
